![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, CTTQ will manufacture Fosaprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist, for Injection, the therapeutic generic equivalent of Emend, and will be sold under the Techdow USA Label.
Lead Product(s): Fosaprepitant
Therapeutic Area: Gastroenterology Product Name: Emend-Generic
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Techdow USA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 22, 2023